ESC 2019 Prof. Verheugt talks about the results of the AFIRE trial, in which monotherapy with rivaroxaban was compared with a combination therapy of rivaroxaban and antiplatelet agents in CAD patients with AF.

An AI model permits point-of-care identification of individuals with a high likelihood of AF, in normal sinus rhythm ECGs, based on subtle findings due to structural changes in the atria.

In a subanalysis of the ENGAGE AF-TIMI 48 study, efficacy and safety of high dose edoxaban was similar in AF patients with and without liver disease.

In the CABANA trial, catheter ablation did not result in a reduction of death, disabling stroke, serious bleeding or cardiac arrest in symptomatic AF patients compared to drug therapy.

A wait-and-see strategy with rate-control drugs was non-inferior to early pharmacologic or electric conversion in achieving sinus rhythm among patients with recent-onset symptomatic AF.

ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

ACC 2019 The AUGUSTUS trial showed less bleeding and fewer hospitalizations without differences in ischemic events with apixaban and no aspirin, as compared with regimens with VKA, aspirin or both.

ACC 2019 Dr. Valentine chaired the press conference on the Apple Heart Study. He summarizes the results and the response to the AF-screening results obtained with Apple Watch.

ACC 2019 The Apple Heart Study in over 400.000 people, showed that Apple Watch could detect AF in 0.5% of participants, after having been alerted by the app as having an irregular heartbeat.

In an exploratory analysis of insurance data, DOAC use reduced stroke or systemic embolism in patients with mitral stenosis and AF compared to warfarin.

An Asian cohort of adults with non-valvular AF and low or very low body weight (<60/50 kg), showed better effectiveness and safety with regular and reduced DOAC dose, compared with warfarin.

Both observational and mendelian randomization analyses suggest that fat-free mass and fat mass are both causally associated with incident AF. The link between fat mass and AF was stronger in women.